NCT01780220已完成1 期
Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- UNICANCER
- 入组人数
- 47
- 试验地点
- 5
- 主要终点
- to determine the maximum tolerated dose and the phase II recommended dose of abiraterone acetate treatment plus prednisone and LH-RH agonist combined with prostate radiotherapy
研究概览
简要总结
As there is no prospective data on the combination of abiraterone and salvage radiotherapy, the aim of this study is to further evaluate the safety profile of abiraterone acetate plus prednisone in patients with prostate cancer who are biochemically relapsing after surgery and undergo salvage radiotherapy with 6-months LH-RH agonist.
The investigators hypothesize that the toxicity profile of both treatments should not potentiate each other. This study will also provide preliminary data on the efficacy of this combination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed prostate adenocarcinoma
- •The patients should have undergone only surgery for localized prostate adenocarcinoma: pT2, pT3 or pT4 with bladder neck involvement
- •pN0: negative lymphadenectomy at the time of prostatectomy
- •At inclusion the patients should have no clinical signs of progressive disease and should be M0 (bone and pelvic scans).
- •≥ 18 years of age with life expectancy ≥ 10 years
- •Performance Status (ECOG) ≤ 1
- •PSA ≤ 0.1 ng/ml after prostatectomy (dosage performed within 2 months after surgery)
- •PSA ≥ 0.2 ng/ml et ≤ 2 ng/ml at the time of inclusion
- •Elevation of PSA over three consecutive assays performed in the same laboratory, with a minimal interval of two months between assays, (PSA nadir level followed by two other progressive assays)
- •At least 6 months between surgery and biochemical relapse
- •Serum potassium ≥ 3.5 mmol/L in the 72 hours before first dose of abiraterone acetate
- •Serum creatinine < 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min
- •Liver function:
- •Serum bilirubin < 1.5 x ULN (except for patients with documented Gilbert's disease) AST and ALT < 2.5 x ULN
- •Patients must be affiliated to a Social Security System.
- •Patient information and written informed consent form signed for both principal and additional research
- •Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
排除标准
- •pN1: histologically-proven lymph node involvement at initial lymphadenectomy
- •Histology other than adenocarcinoma
- •Previous hormone therapy including prior therapy with ketoconazole or other CYP17 inhibitor(s) for prostate cancer.
- •Patients being treated within the last 14 days prior to inclusion with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A4 (Clarithromycin, Ketoconazole, Itraconazole, Voriconazole, Ritanovir, see appendix 11) or requiring those treatments during the study
- •Active or symptomatic viral hepatitis or chronic liver disease
- •Surgical or chemical castration
- •History of cancer, with the exception of basal cell carcinoma or any other cancer treated in the 5 years before inclusion and in complete remission.
- •Previous pelvic radiotherapy
- •Uncontrolled hypertension (defined as systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg). Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy (see appendix 10 for mandatory BP measurement guidelines)
- •Severe and moderate hepatic impairment (Child-Pugh class B and C)
- •Patients with severe and/or uncontrolled medical disease which could compromise participation in the study, such as, but not limited to:
- •Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or cardiac ejection fraction measurement of < 50 % at baseline
- •Known hypersensitivity to any of the study drugs or excipients.
- •Galactosemia, Glucose-galactose malabsorption or lactase deficiency
- •Patients with any psychological, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
- •Individual deprived of liberty or placed under the authority of a tutor.
- •Patients already included in another therapeutic trial with an experimental drug or having been given an experimental drug within a period of 30 days.
研究组 & 干预措施
abiraterone
Experimental
Abiraterone acetate (three dose levels in phase I) + prednisone (10mg/day)+LHRH + Radiotherapy
干预措施: Abiraterone (Drug)
结局指标
主要结局
to determine the maximum tolerated dose and the phase II recommended dose of abiraterone acetate treatment plus prednisone and LH-RH agonist combined with prostate radiotherapy
时间窗: within 11 weeks after Radiotherapy initiation
次要结局
- To evaluate the 3-year biochemical relapse-free survival(3 years)
研究者
研究点 (5)
Loading locations...
相似试验
Unknown
1 期
Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in ChildrenChildhood RhabdomyosarcomaNCT03868852Xinhua Hospital, Shanghai Jiao Tong University School of Medicine48
Unknown
2 期
Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLCNSCLCNCT03801200Hubei Cancer Hospital90
尚未招募
2 期
AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic CancerPancreatic CarcinomaNCT06080854The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School108
招募中
不适用
A prospective study of salvage radiotherapy combined with horrmone therapy for high-risk recurrent prostate cancer after radical prostatectomyRecurrent prostate cancer after radical prostatectomyJPRN-UMIN000030864Department of Urology, Nara Medical University100
已完成
3 期
Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate CancerProstatic Neoplasms, Locally AdvancedNCT01122121Takeda273